Formulation and Drug Delivery, Biologic Drugs

January 6th 2025

The $94 million (€90 million) Series A funding will be used to support the development of the company’s pipeline of nCycles, oral macrocycle drugs that will be focused on validated biologic targets.

December 3rd 2024

Lonza’s new tailored offering leverages the company’s bi-layer capsule manufacturing technology.

November 20th 2024

Under the collaboration, the companies will create and test circVec DNA–LNP formulations with an eye toward potential therapeutic applications.

September 10th 2024

Alternative delivery methods for biologics continues to be explored that offer less invasive, less painful administration.